These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 3643740)

  • 1. Studies on synthetic peptide substrates for F XII enzymes.
    Friberger P; Aurell L; Rees W; Gallimore MJ
    Adv Exp Med Biol; 1986; 198 Pt B():53-61. PubMed ID: 3643740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assay of factor XII in human plasma using prekallikrein or the chromogenic peptide S-2222 as substrates--significance of the functional state of plasma kallikrein.
    Hoem NO; Johannesen S; Briseid K
    Thromb Res; 1989 May; 54(3):197-205. PubMed ID: 2787541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa.
    Tans G; Janssen-Claessen T; Rosing J; Griffin JH
    Eur J Biochem; 1987 May; 164(3):637-42. PubMed ID: 3552674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FXII levels, FXIIa-like activities and kallikrein activities in normal subjects and patients undergoing cardiac surgery.
    Wendel HP; Jones DW; Gallimore MJ
    Immunopharmacology; 1999 Dec; 45(1-3):141-4. PubMed ID: 10615003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assay for Hageman factor (factor XII) in human plasma by means of chromogenic substrate for plasma kallikrein.
    Egberg N; Overmark-Berggren I
    Thromb Res; 1983 Sep; 31(6):875-80. PubMed ID: 6557688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new assay for the determination of factor XII in plasma using a chromogenic substrate and a selective inhibitor of plasma kallikrein.
    Stürzebecher J; Svendsen L; Eichenberger R; Markwardt F
    Thromb Res; 1989 Sep; 55(6):709-15. PubMed ID: 2781533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates.
    McRae BJ; Kurachi K; Heimark RL; Fujikawa K; Davie EW; Powers JC
    Biochemistry; 1981 Dec; 20(25):7196-206. PubMed ID: 6976185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of chromogenic substrates for estimation of indicators of kallikrein-kinin and blood coagulation systems in blood plasma of patients with nephrotic syndrome].
    Baskova IP; Paskhina TS; Poliantseva LR; Iakubovskaia RI; Tiero A
    Vopr Med Khim; 1983; 29(5):96-9. PubMed ID: 6557709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor.
    Schousboe I
    Eur J Biochem; 2003 Jan; 270(1):111-8. PubMed ID: 12492481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coagulation factor XII protease domain crystal structure.
    Pathak M; Wilmann P; Awford J; Li C; Hamad BK; Fischer PM; Dreveny I; Dekker LV; Emsley J
    J Thromb Haemost; 2015 Apr; 13(4):580-91. PubMed ID: 25604127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor XII fragment and kallikrein generation in plasma during incubation with biomaterials.
    van der Kamp KW; van Oeveren W
    J Biomed Mater Res; 1994 Mar; 28(3):349-52. PubMed ID: 7521336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional correlation between kallikrein and factor XII activated in human plasma.
    Briseid K; Hoem NO; Johannesen S; Marthinsen K
    Thromb Res; 1990 Mar; 57(6):945-56. PubMed ID: 1696402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active-site mapping of bovine and human blood coagulation serine proteases using synthetic peptide 4-nitroanilide and thio ester substrates.
    Cho K; Tanaka T; Cook RR; Kisiel W; Fujikawa K; Kurachi K; Powers JC
    Biochemistry; 1984 Feb; 23(4):644-50. PubMed ID: 6370301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preliminary study on the effects of coagulation factor XII on fibrinolysis].
    Hu Y; Wang H; Jiao J; Wang Y; Yu W; Ling X
    Zhonghua Xue Ye Xue Za Zhi; 2000 Sep; 21(9):466-8. PubMed ID: 11877020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serine protease specificity for peptide chromogenic substrates.
    Mattler LE; Bang NU
    Thromb Haemost; 1977 Dec; 38(4):776-92. PubMed ID: 146272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Competitive-protein adsorption in contact activation of blood factor XII.
    Zhuo R; Siedlecki CA; Vogler EA
    Biomaterials; 2007 Oct; 28(30):4355-69. PubMed ID: 17644174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of IgG for the activity of factor XII measured in human plasma.
    Briseid K; Hoem NO; Johannesen S; Vangen AM; Westgaard T
    Scand J Clin Lab Invest; 1996 Dec; 56(8):725-34. PubMed ID: 9034354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The levels of factor XIIa generated in human plasma on an electronegative surface are insensitive to wide variation in the concentration of FXII, prekallikrein, high molecular weight kininogen or FXI.
    Mitropoulos KA
    Thromb Haemost; 1999 Sep; 82(3):1033-40. PubMed ID: 10494760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor XII Osaka: abnormal factor XII with partially defective prekallikrein cleavage activity.
    Iijima K; Arakawa Y; Sugahara Y; Matsushita M; Moriguchi Y; Shimohiro H; Nakagawa M
    Thromb Haemost; 2011 Mar; 105(3):473-8. PubMed ID: 21264442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential binding of factor XII and activated factor XII to soluble and immobilized fibronectin--localization of the Hep-1/Fib-1 binding site for activated factor XII.
    Schousboe I; Nystrøm BT; Hansen GH
    FEBS J; 2008 Oct; 275(20):5161-72. PubMed ID: 18793325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.